Phrontline's TJ101 Shows 6/8 Responses in Urothelial Cancer
SHANGHAI – October 30, 2026 -- Phrontline Biopharma reported partial responses in six of eight response-evaluable urothelial carcinoma patients (75%) treated with its bispecific antibody-drug conjugate (ADC) TJ101, and has dosed the first patient in a Phase Ib trial.
TJ101 produces responses in patients previously treated with EV and pembrolizumab
The data were presented at the ESMO Congress 2026 in Madrid on October 23, 2026. Responders included patients previously treated with enfortumab vedotin (EV) and pembrolizumab. The results are preliminary and come from a small patient group. The company itself cautions that such findings may not predict outcomes in later studies.